

# RECONCILIATION FROM REPORTED REVENUE TO UNDERLYING REVENUE

(BN YEN)	FY2018 <sup>*1</sup> H1	FY2019 H1	vs. PY	
<b>Revenue</b>	<b>880.6</b>	<b>1,660.2</b>	<b>+779.6</b>	<b>+88.5%</b>
Shire Revenue	848.9	-		
<b>Pro-forma Revenue</b>	<b>1,729.5</b>	<b>1,660.2</b>	<b>-69.3</b>	<b>-4.0%</b>
FX effects <sup>*2</sup>				+2.8pp
Divestitures <sup>*3</sup>				+1.0pp
Techpool & Multilab				+0.4pp
XIIDRA & TACHOSIL				+0.7pp
Others				-0.1pp
<b>Underlying Revenue Growth</b>				<b>-0.2%</b>

<sup>\*1</sup> FY2018 H1 revenue is a pro-forma which adds Legacy Shire's 6 month (April - September 2018) revenue previously reported under US GAAP and conformed to IFRS without material differences, excluding Legacy Shire's oncology business, which was sold in August 2018, and converted to JPY using FY2018 actual rate for the period.

<sup>\*2</sup> FX adjustment applies constant FY2018 actual full year average rate to both years (1USD=111 yen, 1EUR=129 yen).

<sup>\*3</sup> Major adjustments are the exclusion of FY2018 H1 revenue of former subsidiaries, Guangdong Techpool Bio-Pharma Co., Ltd., and Multilab Indústria e Comércio de Produtos Farmacêuticos Ltda., both divested in FY2018, and FY2018 H1 and FY2019 H1 revenue of XIIDRA which was divested in July 2019 and TACHOSIL as Takeda agreed in May 2019 to divest this product, with completion of divestiture expected to occur within FY2019.

# REPORTED AND UNDERLYING GROWTH OF LEGACY SHIRE PRODUCT/THERAPEUTIC AREA SALES

(BN YEN)	FY2018 H1		FY2019 H1		Underlying Growth
	Reported <sup>*1</sup>	FX	Reported	FX	
<b>GI</b>	<b>319.8</b>	<b>(1.4)</b>	<b>341.6</b>	<b>(8.2)</b>	<b>+ 8.9%</b>
Legacy Shire	67.7	(0.4)	57.2	(1.3)	- 14.1%
LIALDA	25.3	-0.1	12.2	-0.5	- 50.0%
GATTEX / REVESTIVE	25.3	-0.2	29.3	-0.6	+ 17.0%
<b>Rare Diseases</b>	<b>380.8</b>	<b>(0.2)</b>	<b>327.2</b>	<b>(13.8)</b>	<b>- 10.5%</b>
Rare Metabolic	97.4	+0.5	92.1	(5.7)	+ 1.0%
NATPARA	12.7	-0.1	12.4	-0.1	- 2.2%
Rare Hematology	207.3	(0.3)	174.7	(6.5)	- 12.7%
ADVATE	103.2	+0.3	83.2	-3.3	- 15.9%
ADYNOVATE	28.6	-0.1	29.8	-0.6	+ 5.4%
FEIBA	38.7	-0.1	27.8	-1.5	- 24.4%
Hereditary Angioedema	76.2	(0.4)	60.3	(1.6)	- 19.2%
FIRAZYR	38.5	-0.2	15.3	-0.7	- 58.8%
TAKHZYRO	5.7	+0.0	30.7	-0.6	+ 449.9%
CINRYZE	27.8	-0.2	12.0	-0.3	- 56.0%
<b>PDT Immunology</b>	<b>189.1</b>	<b>(0.7)</b>	<b>191.7</b>	<b>(4.8)</b>	<b>+ 3.6%</b>
Legacy Shire	181.1	(0.7)	183.2	(4.8)	+ 3.4%
Immunoglobulin	145.0	(0.6)	146.5	(3.5)	+ 3.0%
Legacy Shire	139.1	(0.6)	140.1	(3.5)	+ 2.8%
Albumin	30.1	(0.1)	34.1	(1.2)	+ 16.9%
Legacy Shire	29.3	(0.1)	33.3	(1.2)	+ 17.4%
Others	13.9	(0.1)	11.1	(0.1)	- 19.6%
Legacy Shire	12.7	(0.1)	9.9	(0.1)	- 21.7%
<b>Neuroscience</b>	<b>205.0</b>	<b>(1.3)</b>	<b>213.9</b>	<b>(3.9)</b>	<b>+ 5.6%</b>
Legacy Shire	158.5	(0.9)	160.1	(3.3)	+ 2.5%
VYVANSE	126.4	-0.8	131.5	-2.6	+ 5.4%
ADDERALL XR	17.4	-0.1	10.6	-0.1	- 38.7%

<sup>\*1</sup> Pro-forma based Legacy Shire's product sales and therapeutic area sales include Legacy Shire's products. FY2018 H1 revenue is a pro-forma which adds Legacy Shire's 6 month (April - September 2018) revenue previously reported under US GAAP and conformed to IFRS without material differences, excluding Legacy Shire's oncology business, which was sold in August 2018, and converted to JPY using FY2018 actual rate for the period.